Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Design, Development and Evaluation of Solifenacin Succinate Tablets


Affiliations
1 Bapatla College of Pharmacy, Bapatla -522101, Guntur (District), Andhra Pradesh (State), India
2 AKRG College of Pharmacy, Vijayawada, A.P, India
     

   Subscribe/Renew Journal


Solifenacin Succinate is used in the treatment of over active bladder with symptoms of urge urinary incontinence, urgency, and increased urinary frequency, and anti spasmodic. Solifenacin Succinate was launched in 2005 and has been shown in both short and long term clinical trials to fulfill these requirements. Solifenacin is a competitive M3 receptor antagonist with a long half-life (45-68 hours). It is available in two dosage strengths namely a 5 or 10 mg once-daily tablet. Ten different trial batches were carried out using different concentrations of excipients like binder (Methocel E5 premium LV), super disintegrant (sodium starch glycolate, cross carmellose sodium, cross povidone), lubricant (Magnesium stearate), glidant (Aerosil) by direct compression technique. The pre-compression parameters and post compression parameters of Solifenacin Succinate tablets were evaluated. The tablets were evaluated for in-vitro drug release studies. Based on similarity factor f2 cross povidone (1.17%), Methocel E5 premium LV (3%), Magnesium starate (1.47%), Aerosil (0.529%) was selected.

Keywords

Solifenacin Succinate, Urinary Incontinence, Overactive Bladder, Muscarinic Receptor Antagonist, Direct Compression.
Subscription Login to verify subscription
User
Notifications
Font Size


Abstract Views: 332

PDF Views: 0




  • Design, Development and Evaluation of Solifenacin Succinate Tablets

Abstract Views: 332  |  PDF Views: 0

Authors

R. K. V. Naga Sudha
Bapatla College of Pharmacy, Bapatla -522101, Guntur (District), Andhra Pradesh (State), India
V. Sai Kishore
Bapatla College of Pharmacy, Bapatla -522101, Guntur (District), Andhra Pradesh (State), India
Ch. Venu Babu
Bapatla College of Pharmacy, Bapatla -522101, Guntur (District), Andhra Pradesh (State), India
E. Jitendranath
AKRG College of Pharmacy, Vijayawada, A.P, India

Abstract


Solifenacin Succinate is used in the treatment of over active bladder with symptoms of urge urinary incontinence, urgency, and increased urinary frequency, and anti spasmodic. Solifenacin Succinate was launched in 2005 and has been shown in both short and long term clinical trials to fulfill these requirements. Solifenacin is a competitive M3 receptor antagonist with a long half-life (45-68 hours). It is available in two dosage strengths namely a 5 or 10 mg once-daily tablet. Ten different trial batches were carried out using different concentrations of excipients like binder (Methocel E5 premium LV), super disintegrant (sodium starch glycolate, cross carmellose sodium, cross povidone), lubricant (Magnesium stearate), glidant (Aerosil) by direct compression technique. The pre-compression parameters and post compression parameters of Solifenacin Succinate tablets were evaluated. The tablets were evaluated for in-vitro drug release studies. Based on similarity factor f2 cross povidone (1.17%), Methocel E5 premium LV (3%), Magnesium starate (1.47%), Aerosil (0.529%) was selected.

Keywords


Solifenacin Succinate, Urinary Incontinence, Overactive Bladder, Muscarinic Receptor Antagonist, Direct Compression.